Table III.
Characteristics of responders and non-responders to RICER (n = 15)
| Characteristic | Responders | Non-responders |
|---|---|---|
| Patients, N | 11 | 4 |
| Subtype, n | ||
| GCB DLBCL | 5 | 0 |
| Non-GCB DLBCL | 6 | 4 |
| First-line therapy, n | ||
| R-CHOP | 9 | 3 |
| High-dose therapy | 2 | 1 |
| Response to first-line therapy, n | ||
| No response | 3 | 3 |
| Response (duration) | 8 (3 > 12 months; 5 < 12 months) | 1 (4 months) |
RICER, rituximab, ifosfamide, carboplatin, etoposide, lenalidomide; DLBCL, diffuse large B-cell lymphoma; GCB, germinal B-cell-like; R-CHOP, rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisone.